Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 425809 on Midazolam Pharmacokinetics in Healthy Males
NCT05258110Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iclepertin in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point up to 12 hours and Maximum Measured Concentration of Midazolam in Plasma up to 12 hours. Started Mar 2022; status: completed.
02
Drugs
iclepertin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05258110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258110.